N. Uboha

发表

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

N. Lennon, A. Giobbie-Hurder, R. Mak, 2022, The Lancet. Oncology.

Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors

J. Eickhoff, D. Deming, S. Lubner, 2020, Investigational New Drugs.

A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer

J. Lacy, J. Kortmansky, H. Hochster, 2020, Cancer.

Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.

J. Kratz, S. Lubner, N. Uboha, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in biomarker-based clinical trials for patients with gastrointestinal malignancies

J. Kratz, N. Uboha, M. Patel, 2022, Expert Review of Precision Medicine and Drug Development.

A Phase I Dose Escalation Study of Neoadjuvant SBRT plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.

Steve Y. Cho, S. Reeder, M. Ritter, 2020, International journal of radiation oncology, biology, physics.

Cytoplasmic localization of calcium/calmodulin‐dependent protein kinase I‐α depends on a nuclear export signal in its regulatory domain

A. Nairn, M. Picciotto, T. T. Stedman, 2004, FEBS letters.

Treatment Approach to Adenocarcinoma of the Ampulla of Vater

N. Uboha, M. Patel, 2021, Current Treatment Options in Oncology.

AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma.

N. Uboha, M. Patel, Monica A Patel, 2022, JAMA oncology.

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.

M. Borad, J. Furuse, H. Chang, 2019, Journal of Clinical Oncology.

Motion‐robust, blood‐suppressed, reduced‐distortion diffusion MRI of the liver

David R. Rutkowski, A. Guidon, D. Hernando, 2022, Magnetic resonance in medicine.

Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma.

Vanessa L. Horner, K. Matkowskyj, Erica F Reinig, 2020, Translational gastroenterology and hepatology.

Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity

M. Burkard, J. Kratz, I. Ong, 2021, bioRxiv.

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.

J. Kratz, Menggang Yu, D. Deming, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience

Y. Janjigian, G. Ku, Z. Wainberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of ezrin in glial tubes in the adult subventricular zone and rostral migratory stream

M. Picciotto, R. Beech, M. Cleary, 2006, Neuroscience.

Primary and acquired resistance to biologic therapies in gastrointestinal cancers.

D. Deming, S. Lubner, N. Uboha, 2017, Journal of gastrointestinal oncology.

TAS-102: a novel antimetabolite for the 21st century.

H. Hochster, N. Uboha, 2016, Future oncology.

Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board.

Ruth Warren, Mark E. Burkard, Joshua M. Lang, 2017, JCO precision oncology.

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

W. Messersmith, C. Leichman, L. Leichman, 2014, Cancer Chemotherapy and Pharmacology.

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

P. LoRusso, P. Ott, J. Bendell, 2021, Journal for ImmunoTherapy of Cancer.

Editorial About: “A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma”

Patrick B. Schwartz, S. Weber, N. Uboha, 2019, Annals of Surgical Oncology.

Advances in Immuno-oncology for the Treatment of Colorectal and Anal Cancers

D. Deming, N. Uboha, P. Grogan, 2021, Digestive Disease Interventions.

A Calcium- and Calmodulin-Dependent Kinase Iα/Microtubule Affinity Regulating Kinase 2 Signaling Cascade Mediates Calcium-Dependent Neurite Outgrowth

A. Nairn, M. Picciotto, M. Flajolet, 2007, The Journal of Neuroscience.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

J. Lacy, Z. Wainberg, T. Alcindor, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

F. Meric-Bernstam, P. LoRusso, J. Harding, 2020 .

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

O. Vasiljeva, G. V. van Dongen, F. Meric-Bernstam, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Microwave ablation for colorectal cancer metastasis to the liver: a single-center retrospective analysis.

S. Wells, J. Hinshaw, M. Lubner, 2021, Journal of gastrointestinal oncology.

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

S. Piha-Paul, M. Milhem, D. Purkayastha, 2019, Journal of Clinical Oncology.

The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).

A. Barzi, J. Lennerz, R. Kelley, 2020 .

Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

H. Lenz, W. Messersmith, H. Hochster, 2014, Cancer Chemotherapy and Pharmacology.

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

P. LoRusso, A. El-Khoueiry, A. Naing, 2019, Journal of Clinical Oncology.

Adjuvant Chemotherapy for Stage II Rectal Cancer.

E. Borden, S. Glasgow, D. Deming, 2015, Seminars in oncology.

Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma

Vanessa L. Horner, K. Matkowskyj, Erica F Reinig, 2020, Translational Gastroenterology and Hepatology.

Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.

N. Pavlakis, A. Nagrial, M. Overman, 2023, Journal of Clinical Oncology.

Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

J. Eickhoff, D. Deming, J. Maloney, 2019, Journal of Clinical Oncology.

Treatment of Oligometastatic GI Cancers.

N. Uboha, C. T. Marcinak, Patrick B Schwartz, 2024, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).

David H. Kim, J. Eickhoff, D. Abbott, 2020 .

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

J. Lacy, J. Kortmansky, S. Boerner, 2023, British journal of cancer.